These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1421000)

  • 1. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers.
    Gotlieb WH; Abrams JS; Watson JM; Velu TJ; Berek JS; Martínez-Maza O
    Cytokine; 1992 Sep; 4(5):385-90. PubMed ID: 1421000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines in peritoneal fluid of ovarian neoplasms.
    de Lima CA; Silva Rodrigues IS; Martins-Filho A; Côbo Micheli D; Martins Tavares-Murta B; Candido Murta EF; Simões Nomelini R
    J Obstet Gynaecol; 2020 Apr; 40(3):401-405. PubMed ID: 31476946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
    Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
    Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
    Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
    Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
    Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of IL-10 in patients with ovarian carcinoma.
    Mustea A; Könsgen D; Braicu EI; Pirvulescu C; Sun P; Sofroni D; Lichtenegger W; Sehouli J
    Anticancer Res; 2006; 26(2C):1715-8. PubMed ID: 16617566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer.
    Plante M; Rubin SC; Wong GY; Federici MG; Finstad CL; Gastl GA
    Cancer; 1994 Apr; 73(7):1882-8. PubMed ID: 8137215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomyxoma peritonei: inflammatory responses in the peritoneal microenvironment.
    Lohani K; Shetty S; Sharma P; Govindarajan V; Thomas P; Loggie B
    Ann Surg Oncol; 2014 May; 21(5):1441-7. PubMed ID: 24046117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer.
    Moradi MM; Carson LF; Weinberg B; Haney AF; Twiggs LB; Ramakrishnan S
    Cancer; 1993 Oct; 72(8):2433-40. PubMed ID: 8402460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
    Matte I; Garde-Granger P; Bessette P; Piché A
    BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
    Nowak M; Glowacka E; Szpakowski M; Szyllo K; Malinowski A; Kulig A; Tchorzewski H; Wilczynski J
    Neuro Endocrinol Lett; 2010; 31(3):375-83. PubMed ID: 20588232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
    Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
    Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant Ascites Promote Adhesion of Ovarian Cancer Cells to Peritoneal Mesothelium and Fibroblasts.
    Uruski P; Mikuła-Pietrasik J; Pakuła M; Budkiewicz S; Drzewiecki M; Gaiday AN; Wierzowiecka M; Naumowicz E; Moszyński R; Tykarski A; Książek K
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells.
    Loercher AE; Nash MA; Kavanagh JJ; Platsoucas CD; Freedman RS
    J Immunol; 1999 Dec; 163(11):6251-60. PubMed ID: 10570318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
    Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
    Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.
    da Silva RF; Yoshida A; Cardozo DM; Jales RM; Paust S; Derchain S; Guimarães F
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28513532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acidic ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients.
    Yang Q; Bae G; Nadiradze G; Castagna A; Berezhnoy G; Zizmare L; Kulkarni A; Singh Y; Weinreich FJ; Kommoss S; Reymond MA; Trautwein C
    J Transl Med; 2022 Dec; 20(1):581. PubMed ID: 36503580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
    Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG
    Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer.
    Santin AD; Bellone S; Ravaggi A; Roman J; Smith CV; Pecorelli S; Cannon MJ; Parham GP
    BJOG; 2001 Aug; 108(8):804-8. PubMed ID: 11510703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.